【结 构 式】 |
【药物名称】ZD-4190 【化学名称】N-(4-Bromo-2-fluorophenyl)-7-[2-(1H-1,2,3-triazol-1-yl)ethoxy]-6-methoxyquinazoline-4-amine hydrochloride 【CA登记号】257938-36-6 【 分 子 式 】C19H17BrClFN6O2 【 分 子 量 】495.74174 |
【开发单位】AstraZeneca (Originator) 【药理作用】ONCOLYTIC DRUGS, Angiogenesis Inhibitors, Inhibitors of Signal Transduction Pathways, Tyrosine Kinase Inhibitors |
合成路线1
Quinazolinone (III) was prepared by treatment of aminobenzamide (I) with Gold's reagent (II) in refluxing dioxan. Subsequent chlorination using thionyl chloride gave chloroquinazoline (IV). Nucleophilic displacement of the chlorine atom of (IV) with 4-bromo-2-fluoroaniline (V) yielded the anilinoquinazoline (VI). The benzyl group of (VI) was then cleaved with trifluoroacetic acid, and the resulting hydroxyquinazoline (VII) was finally coupled with (hydroxyethyl)triazole (VIII) using DEAD and PPh3 to furnish the title compound.
【1】 Thomas, A.P.; Johnstone, C.; Hennequin, L.F.; et al.; Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. J Med Chem 1999, 42, 26, 5369. |
中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
---|---|---|---|---|---|---|
(I) | 31528 | 2-amino-4-(benzyloxy)-5-methoxybenzamide | C15H16N2O3 | 详情 | 详情 | |
(II) | 31529 | N-([[(E)-(dimethylamino)methylidene]amino]methylene)-N-methylmethanaminium | C6H14N3 | 详情 | 详情 | |
(III) | 31530 | 7-(benzyloxy)-6-methoxy-4(3H)-quinazolinone | C16H14N2O3 | 详情 | 详情 | |
(IV) | 31531 | benzyl 4-chloro-6-methoxy-7-quinazolinyl ether; 7-(benzyloxy)-4-chloro-6-methoxyquinazoline | C16H13ClN2O2 | 详情 | 详情 | |
(V) | 14723 | 4-Bromo-2-fluorophenylamine; 4-Bromo-2-fluoroaniline | 367-24-8 | C6H5BrFN | 详情 | 详情 |
(VI) | 31532 | 7-(benzyloxy)-N-(4-bromo-2-fluorophenyl)-6-methoxy-4-quinazolinamine; N-[7-(benzyloxy)-6-methoxy-4-quinazolinyl]-N-(4-bromo-2-fluorophenyl)amine | C22H17BrFN3O2 | 详情 | 详情 | |
(VII) | 31533 | 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-quinazolinol | C15H11BrFN3O2 | 详情 | 详情 | |
(VIII) | 31534 | 2-(1H-1,2,3-triazol-1-yl)-1-ethanol | C4H7N3O | 详情 | 详情 |